Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BARD1
REST API REST API
Homo sapiens
BARD1 is differentially expressed in 339 experiments: 141 organism parts: bone marrow, thymus, ... (139 more);, 223 disease states: normal, glioblastoma, ... (221 more);, 108 cell types 399 cell lines 50 compound treatments and 78 other conditions.
Orthologs HOS4 (Saccharomyces cerevisiae)   Bard1 (Mus musculus)   Q5ZKJ1_CHICK (Gallus gallus)   BARD1 (Danio rerio)   ENSCING00000013868 (Ciona intestinalis)   BARD1 (Bos taurus)   Bard1 (Rattus norvegicus)   bard1 (Xenopus laevis)   BARD1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term ligase activity, regulation of phosphorylation, protein binding, DNA repair, cytoplasm, intracellular, protein ubiquitination, negative regulation of apoptosis, kinase binding, cell cycle arrest, metal ion binding, spermatogenesis, negative regulation of mRNA 3'-end processing, positive regulation of apoptosis, nucleus, protein heterodimerization activity, ubiquitin-protein ligase activity, ubiquitin ligase complex, protein homodimerization activity, negative regulation of protein export from nucleus, tissue homeostasis, response to DNA damage stimulus, RNA binding, zinc ion binding, positive regulation of protein catabolic process, protein K6-linked ubiquitination, BRCA1-A complex, BRCA1-BARD1 complex
InterPro Term Ankyrin_rpt, Ankyrin_rpt-contain_dom, Znf_RING, BRCT
UniProt Accession Q99728, C9IYG1, C9J6M1, E7EUI3, F8WCG2
Gene-Disease Assocation BREAST CANCER
Search EB-eye ENSG00000138376
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (43 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
K562
3
E-MTAB-37, E-GEOD-24147, E-GEOD-96
BT474
2
E-MTAB-37, E-MEXP-440
HepG2
2
E-GEOD-21154, E-MTAB-37
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MOLT4
2
E-MTAB-62, E-MTAB-37
393 more value(s).


Cell type

studied in E-GEOD-20193, E-MEXP-1121, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (52 experiments)

Factor Value U/D Experiments
mononuclear
2
E-GEOD-13987, E-GEOD-26672
adipocyte
2
E-AFMX-5, E-TABM-145
1
2
E-TABM-130, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
adult native RPE from 89 y.o. donor
1
E-GEOD-18811
Monocytes
1
E-GEOD-21909
102 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-MEXP-2280, ... (77 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-MTAB-62, E-MEXP-2034, E-GEOD-96, E-MEXP-1327
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
glioblastoma
2
3
E-GEOD-4290, E-GEOD-6014, E-MTAB-62, E-MEXP-567, E-MTAB-37 ... (5 experiments)
colon carcinoma
1
2
E-MTAB-37, E-MTAB-62, E-GEOD-3726
acute lymphoblastic leukemia
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-96
217 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-1417, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (31 experiments)

Factor Value U/D Experiments
none
5
10
E-GEOD-5824, E-GEOD-1740, E-MEXP-1601, E-GEOD-412, E-GEOD-995, ... (15 experiments)
bicalutamide and dihydrotestoterone
1
E-GEOD-7708
HMB-PP (phosphoantigen)
1
E-MEXP-1601
estradiol
1
E-GEOD-20081
endotoxin
1
E-GEOD-3026
saline
1
E-GEOD-3026
44 more value(s).


Age at diagnosis

studied in E-GEOD-21653, E-GEOD-4922

Factor Value U/D Experiments
36
2
1
E-GEOD-21653
93 years
1
1
E-GEOD-4922


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-860, E-MEXP-1251, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, ... (10 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-4922

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-22593, E-GEOD-20115, E-GEOD-18005, E-TABM-868, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-20540, E-GEOD-22278, E-GEOD-1692, E-TABM-263, E-MEXP-1220, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-2748

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (31 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561, E-GEOD-6802, E-GEOD-360

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2508, E-GEOD-7307, E-GEOD-16363

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (8 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-6532, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Tumor size
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.308 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM